Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 891 publications.

Malec L, Carcao M, Mathias M, Kragh N, Dumont J, Willemze A, Bystricka L, Wilson A, DiBenedetti D. Experiences with efanesoctocog alfa: exit interviews with caregivers of previously treated patients with hemophilia a from the XTEND-Kids phase 3 clinical trial. Presentation to be given at the 65th ASH Annual Meeting & Exposition 2023; December 10, 2023. San Diego, CA.

Escobar MA, Fan QA, Mokdad AG, Tarantino MD, Burgess B, Hawe E, Fernandez M, Bullano M. Clinical outcomes of noninhibitor patients with hemophilia a switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies. Presentation to be given at the 65th ASH Annual Meeting & Exposition 2023; December 9, 2023. San Diego, CA.

Eriksson M, Andersson Galijatovic E, Schiel A, Brodtkorb T-H. The FINOSE collaboration – joint health technology assessment in the Nordics. Presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark.

Onukwugha E, Earnshaw S, Pizzi L, Shukla S. Professional competencies for health economics and outcomes research – 2023 update to the ISPOR Competencies Framework. Presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark.

Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.

Earnshaw S, Brodtkorb T-H, Mullins D. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Doward L, Hawe E, Lloyd A, Wolowacz S. Estimating health-state utility for economic models in clinical trials and real-world studies. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark.

Handels R, Wimo A, Skoldunger A, Tate A, Winblad B, Silvertand D, Nguyen L, Jonsson L, Grimm S, Aye S, Herring W. Open-source model framework for health-economic evaluation of early treatment in Alzheimer's disease. Presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark.

Earnshaw S. Budget impact analysis: a 6-step approach. Presented at the UNC School of Pharmacy AMCP P&T Bootcamp event; October 25, 2023. Chapel Hill, NC.

Earnshaw S. Health economics and outcomes research. Presented at NC State Industrial Engineering course; October 25, 2023. Raleigh NC.

Ozdemir S, Hollin I, Gonzalez JM, Poulos C, Reed S. Exploring stated-preference methods for values clarification for medical decision making. Presented at the SMDM 45th Annual North American Meeting; October 23, 2023. Philadelphia, PA.

Boeri M, Heidenreich S, Cappelleri JC, Vass C, Mt-Isa S, Necdet G, Robert V, Garczarek U, Saint-hilary G, Colopy M, Krucien N, Sepulveda JMG. Sample size decisions for discrete choice experiments in pharmaceutical and health care applications. Presented at the SMDM 45th Annual North American Meeting; October 23, 2023. Philadelphia, PA.

DiBenedetti D, Doward L. Innovations in in-trial interviews: novel approaches to capturing the patient experience in quality of life research. Presented at the ISOQOL 30th Annual Conference; October 21, 2023. Calgary, Canada.

Rockwood N, Qin S, Yarr S. Estimating change score/responsiveness correlations among ordinal measures. Presented at the ISOQOL 30th Annual Conference; October 20, 2023. Calgary, Canada.

Vass C, Penton H, Boeri M. Incorporating patient outcomes, preferences, and perspectives into HTA. Presented at the Virtual PSI Scientific Meeting; October 18, 2023.

DiBenedetti D, Doward L. Design considerations for successful in-trial interviews: the who, what, when, where, and how. Presented at the ISOQOL 30th Annual Conference; October 18, 2023. Calgary, Canada.

Khurana N, Hicks KA, Carrico J, Jacobson E, Farnham PG. Modeling the impact of injectable versus oral pre-exposure prophylaxis (PrEP) on HIV incidence and cost outcomes in the United States. Presentation to be given at the 2023 INFORMS Annual Meeting; October 16, 2023. Phoenix, AR.

Barbieri M, Senese F, Mellott CE, Boccalini S, Carrico J, Bechini A, Talbird SE, Chen Y-H, Bencina G. Public health impact and return on investment of the pediatric national immunization program in Italy. Presented at the Italian Society of Hygiene, Preventive Medicine, and Public Health Conference; October 12, 2023. Cernobbio, Italy.

Karcher H, Hawe E, Jaksa A. External control arms - application, key methods, and acceptability. Presented at the ISPOR Educational Webinar Series; October 10, 2023.

Thomsen RW, Andersen IT, Kristensen FP, Munch PV, Pladevall-Vila M, Johannes C, Saigi-Morgui N, Ziemiecki R, Layton J, Vizcaya D, Gay A, Farjat A, Liu F, Oberprieler N, Christiansen CF. Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform. Presented at the 59th Annual Meeting European Association for the Study of Diabetes (EASD) 2023; October 4, 2023. Hamburg, Germany.

Vass C, Seo J, von Butler L, Zhang Y. Innovative uses of technology to advance health preference research. Presented at the ISPOR Webinar; September 20, 2023.

Garcia de Albeniz Martinez X, Chirila C, Hernan MA, Leaver DRM. Ready or not, here come estimands! The emerging attention to causal estimands in real-world evidence studies. Presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada.

Margulis AV, Bateman BT, Hernandez-Diaz S, Huybrechts KF. Modern pregnancy pharmacoepidemiology: non-live birth outcomes. Presented at the 39th ICPE Annual Conference; August 24, 2023. Halifax, Canada.

Hernan ME, Layton D, Garcia de Albeniz Martinez X. Advanced methods II: how to make sure immortal time never happens. Presented at the 39th ICPE Annual Conference; August 24, 2023. Halifax, Canada.

Gilsenan AW, Hammad TA, Juhaeri J, Mansfield C, Levitan BS. Weighting the benefits & risks: the science and methods of benefit-risk assessment in drug development. Presented at the 39th ICPE Annual Conference; August 23, 2023. Halifax, Canada. Previously presented at the 2022 ICPE Conference.

Bratton EW, Hester L, Garcia de Albeniz Martinez X. Real-world evidence (RWE) generation for rare disease drug development and orphan drug approvals. Presented at the 39th ICPE Annual Conference; August 23, 2023. Halifax, Canada. Previously presented at the 2022 ICPE Conference.

Fox L. Transformations of random variables. Presented at the Mathematical Association of America (MAA) Mathfest 2023; August 4, 2023. Tampa, FL.

Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination in 50-59-year-olds: primary care knowledge and practices. Presented at the National Medical Association ( NMA) 2023 Annual Convention and Scientific Assembly; July 29, 2023. New Orleans, LA.

Moehler M, Wyrwicz L, Blum S, Chen C, Wang J, Davenport E, Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer(GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C). Presented at the ESMO World Congress on Gastrointestinal Cancer 2023; June 28, 2023. Barcelona, Spain.

Margulis A. Validation of events in database studies on pregnancy pharmacoepidemiology. Presented at the Bordeaux PharmacoEpi Festival 2023; May 24, 2023. Talence, France.

Willke R, McElwee N, Cole A, Berger M, Earnshaw S. Towards broader relevance for HEOR: an HSPC visioning project. Presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Karcher H, Hawe E, Gatto N, Jonsson P. External control arms (ECA) in phase 3 trials: what is needed now and in the future to enable acceptance with regulatory and HTA bodies? Presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Hundt Golden A, Gabriel MH, Price M. The Delphi Panel—from discord to actionable HEOR insights. Presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Fox L. The effect of governance structures on optimal control of two-patch epidemic models. Presented at the Virtual 2023 Virginia Tech MathBio Seminar; April 26, 2023. Previously presented at the Joint Mathematics Meetings 2023.

Fox L, Murphy S. AP precalculus: gift or gimmick? Presented at the Virtual Joint Meetings of the Mathmatical Association of America (MAA) FL; February 17, 2023.

Fox L. The effect of governance structures on optimal control of two-patch epidemic models. Presented at the Virtual Joint Meetings of the Mathematical Association of America (MAA) FL; February 17, 2023. Previously presented at the Joint Mathematics Meetings (JMM) 2023.

Fox L. The effect of governance structures on optimal control of two-patch epidemic models. Presented at the Joint Mathematics Meetings (JMM) 2023; January 7, 2023. Boston, MA.

Fox L. Building an infectious disease modeling “lab” at a small liberal arts college. Presented at the Joint Mathematics Meetings (JMM) 2023; January 4, 2023. Boston, MA.

Garcia de Albeniz Martinez X, Hampson L. Introduction to the ICH E9(R1) estimand and target trial emulation frameworks, and their role in the design and analysis of RWE studies. Presented at the ASA NJ Chapter Webinar Series; December 2, 2022.

Garcia de Albeniz Martinez X. Continuation of annual screening mammography and breast cancer mortality in women older than 70 years. Presented at the Vac4EU Virtual Journal Club; November 25, 2022.

Herring WL. Determining the value of disease-modifying therapies for Alzheimer's disease. Presented at the JIM Symposium at Karolinska Institutet; November 11, 2022. Stockholm, Sweden.

Ysander M, Caplanusi I, Arana A. True adverse reaction or not: that's the question. Presented at the Global Forum for Qualified Persons for Pharmacovigilance; November 9, 2022. Amsterdam, Netherlands.

Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP. Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Gilsenan A, Kawai A. Considerations for planning safety surveillance studies of COVID-19 vaccine. Presented at the North American Chapter of the International Society of Pharmacovigilance (NASoP); November 8, 2022.

Brodtkorb TH. Does the choice of cost-effectiveness model approach matter? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Wolowacz S. Incorporating informal care considerations in HTA. Presented at the ISPOR Europe 2022; November 7, 2022.

Garcia de AlbenizMartinez X. Target trial emulation and pharmacovigilance. Presented at the North American Chapter of the International Society of Pharmacovigilance (NASoP); November 7, 2022.

Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L, Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France. Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.

Emery L, Hicks JC. Inclusive language: best practices and practical applications for medical writers and editors. Presented at the 2022 AMWA Medical Writing & Communication Conference; November 5, 2022. Denver, CO. Previously presented at the Virtual American Medical Writers Association (AMWA) Carolina Chapter Spring Conference.

Musetti Jenkins S. Plain language summaries and beyond: tips and tricks for improving outreach and engagement. Presented at the 2022 AMWA Conference; November 4, 2022. Denver, CO.